ebv peptide mix  (Proimmune)

Journal: Journal of Virology

Article Title: Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity

doi: 10.1128/JVI.02002-20

Figure Lengend Snippet: CD8 + T-cell polyfunctionality analysis after ex vivo expansion with specific SARS CoV-2 peptides derived from the SARS-CoV-2 NC. (a and c) Representative dot plots showing effector cytokine production and degranulation level of CD8 + T cells stimulated with RTATKAYNV (a) and IIWVATEGA (c) peptides. The CD8 + T cells were derived from two HLA-A*02-positive SARS-CoV-2 convalescent donors. PBMCs from an HLA-A*02-negative SARS-CoV-2 convalescent donor were used as a negative control. The clinical samples were obtained at 1 to 2 months after SARS-CoV-2 recovery. (b and d) Bar charts represent the effector profiles of RTATKAYNV (b)- and IIWVATEGA (d)-specific CD8 + T cells. PBMCs expanded with EBV peptides were used as positive control. Pies depict the distribution of mono-, bi-, tri-, and tetrafunctional cells within specific CD8 + T cells.

Article Snippet: The rested PBMCs ([3 to 5] × 10 6 cells) were incubated in the presence of 5 μM of SARS-CoV-2 peptide pools or Epstein-Barr Virus (EBV) peptide mix (MACS GMP PepTivator EBV select, Miltenyi Biotec) for 1 h. Two SARS-CoV-2 peptides derived from the NC ( RTATKAYNV and IIWVATEGA ; 5 μM for each peptide) were used to stimulate PBMCs for 1 h. The EBV peptide mix (resuspended at 100 μg/ml in DMSO) was used for a positive control (MACS GMP PepTivator EBV Select; Miltenyi Biotec).

Techniques: Ex Vivo, Derivative Assay, Negative Control, Positive Control

Journal: Frontiers in Oncology

Article Title: Biological Predictors of De Novo Tumors in Solid Organ Transplanted Patients During Oncological Surveillance: Potential Role of Circulating TERT mRNA

doi: 10.3389/fonc.2021.772348

Figure Lengend Snippet: Biological parameters in the 49 SOT patients after stratification by tumor occurrence.

Article Snippet: CMV, EBV, Survivin, TERT peptide mixes (ProImmune, Oxford UK; 0.2ng/mL of each peptide mix) or unspecific stimuli (0.5mg/mL αCD3/αCD28) were resuspended in CTL-test Medium, plated in triplicate and incubated for 10-20 minutes.

Techniques:

Journal: Frontiers in Oncology

Article Title: Biological Predictors of De Novo Tumors in Solid Organ Transplanted Patients During Oncological Surveillance: Potential Role of Circulating TERT mRNA

doi: 10.3389/fonc.2021.772348

Figure Lengend Snippet: Cox regression analysis evaluating the associations between baseline demographic, clinical or biological parameters and tumor onset.

Article Snippet: CMV, EBV, Survivin, TERT peptide mixes (ProImmune, Oxford UK; 0.2ng/mL of each peptide mix) or unspecific stimuli (0.5mg/mL αCD3/αCD28) were resuspended in CTL-test Medium, plated in triplicate and incubated for 10-20 minutes.

Techniques: